Introduction
tissue injury, inflammation, infections, hypoglycemia, diabetic, hypoglycemic, TG, metabolic illness, T2DM, tissue damage
TYPE 2 DIABETES MELLITUS, INFLAMMATION, INFECTIONS, HYPOGLYCEMIA, INFECTION SITE, INSULIN RESISTANCE, INFLAMMATION, HYPERTRIGLYCERIDEMIA, OXIDATIVE STRESS, DISEASES
Type 2 diabetes mellitus (T2DM) is a chronic metabolic illness in which the patient’s capability to produce sufficient amounts of insulin is diminished or patients display insulin resistance; thus, the capability of insulin to accomplish its normal function becomes disrupted [Inflammation is recognized as a protective immune response to infections and tissue injury causing the migration of immune cells and plasma proteins to the infection site or tissue damage. Although inflammation is a useful response to the body and may be addressed quickly, uncontrolled inflammatory reactions can result in excessive or long-term tissue damage, leading to the development of acute or chronic inflammatory illnesses [Recently, Bostrom et al. [Previous study has illustrated that inflammatory processes and oxidative stress are suppressed by situin-1 (SIRT1) [Glimepiride, a second-generation sulfonylurea, stimulates insulin release and can be utilized as monotherapy or in combination with other oral hypoglycemic agents or insulin. Glimepiride has a lower risk of hypoglycemia in comparison with other sulfonylureas. It has been shown to have extra-pancreatic effects such as stimulating lipogenesis and glycogenesis [Several studies in recent years have demonstrated the importance of omega-3 supplementation including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) when treating various diseases. For instance, in subjects with residual hypertriglyceridemia, the addition of omega-3 fatty acids to atorvastatin improved triglycerides (TG) and non-HDL-C levels in comparison with atorvastatin alone [The present study aims to assess the effect of coadministration of omega-3 fatty acids and glimepiride as a hypoglycemic drug on the blood levels of irisin, sirtuin-1, glucose homeostasis, and the lipid profile of type 2 diabetic patients.The primary outcome in this trial was the improvement of FBG, HbA1C %, lipid profile (total cholesterol (TC), triglycerides (TG), HDL-cholesterol (HDL-C), and LDL-cholesterol (LDL-C)), and atherogenic index of plasma (AIP). Secondary outcomes included the change of serum levels of the measured biomarkers irisin and sirtuin-1 after 12 weeks of intervention.